The company’s EBITDA surged 72% to ₹285 crore, with margins widening by 400 basis points to 12.5%. This improvement reflects a combination of higher capacity utilization, disciplined pricing, and operational excellence across its 17 global manufacturing sites. While the firm remains in a net loss position of ₹69 crore, this represents a 32% improvement compared to the same period last year. Chairperson Nandini Piramal noted that all three business units delivered mid-to-high teens revenue growth, signaling successful execution despite a volatile external environment.

Driving these results was the Contract Development and Manufacturing Organization (CDMO) segment, which saw 19% growth, supported by robust order inflows and expanded commercial capabilities. In the hospital generics space, the company maintained its 48% value share in the US Sevoflurane market. Meanwhile, the consumer healthcare business benefited from a 23% increase in its power brands and a 40% jump in e-commerce sales. Regulatory compliance remains a pillar for the company, highlighted by the US FDA’s recent issuance of an Establishment Inspection Report for the Sellersville facility, maintaining the firm’s zero-OAI status.